Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 111
Filter
1.
Clin Microbiol Infect ; 26(5): 645.e1-645.e8, 2020 May.
Article in English | MEDLINE | ID: mdl-31610300

ABSTRACT

OBJECTIVES: Quantifying IgG antibodies to pertussis toxin (PT) is the most specific and sensitive method for the serodiagnosis of a Bordetella pertussis infection. Since PT is a component of acellular pertussis vaccines, anti-PT IgG is also induced by vaccination, precluding pertussis serodiagnosis based exclusively on anti-PT IgG in recently vaccinated subjects. Here, we aim to identify additional B. pertussis-specific serological markers that can discriminate between infection and recent vaccination. METHODS: The clinical usefulness of measuring IgA directed to the vaccine antigen PT and IgG directed to non-vaccine antigens (Fim2/3, LPS, ACT, CatACT) was evaluated in nine well characterized subject groups, aged 10-89 years (n = 390). Serum anti-PT IgG levels (>125 IU/mL) served as an indicator for a recent B. pertussis infection. Comparing symptomatic pertussis-infected subjects (n = 140) with recently vaccinated, non-infected subjects (n = 100) revealed the optimal cut-off, accuracy, sensitivity and specificity for each single parameter. RESULTS: For pertussis diagnosis in recently vaccinated subjects, the measurement of anti-PT IgA (cut-off 15 IU/mL) and anti-ACT IgG (cut-off 15 U/mL) resulted in accuracies of 95% (91.5-97.1) and 87.5% (82.7-91.1), sensitivities of 92.9% (87.4-96.0) and 83.6% (76.5-88.8) and specificities of 98% (93.0-99.4) and 93% (86.3-96.6), respectively. Comparing anti-PT IgA levels between the youngest (10-19 years, n = 38) and oldest (70-89 years, n = 17) age groups revealed an age-dependent increase in antibody levels in pertussis-infected subjects (p < 0.0001). CONCLUSIONS: Reflex testing of anti-PT IgA and anti-ACT IgG improves pertussis serodiagnosis in recently vaccinated symptomatic subjects with elevated anti-PT IgG levels. Furthermore, both markers can discriminate between vaccination and recent infection in pertussis serosurveillance studies.


Subject(s)
Antigens, Bacterial/immunology , Bordetella pertussis/immunology , Pertussis Toxin/immunology , Pertussis Vaccine/administration & dosage , Serologic Tests/methods , Whooping Cough/diagnosis , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Child , Female , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Male , Middle Aged , Pertussis Vaccine/immunology , Sensitivity and Specificity , Vaccination , Whooping Cough/blood , Whooping Cough/pathology , Whooping Cough/prevention & control , Young Adult
2.
Vaccine ; 31(51): 6136-43, 2013 12 09.
Article in English | MEDLINE | ID: mdl-23850416

ABSTRACT

OBJECTIVE: The investigational AS04-adjuvanted herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) subunit prophylactic vaccine ('HSV vaccine'; GlaxoSmithKline Vaccines) has been shown to be well tolerated in adults, but limited data exist for pre-teen and adolescent girls, a likely target population. The primary objective of this study was to compare the occurrence of serious adverse events (SAEs) over 12 months between HSV vaccine recipients and saline recipients (placebo control group) in pre-teen and adolescent girls. The immunogenicity of the HSV vaccine was also assessed. METHODS: Healthy girls aged 10-17 years, stratified by age (10-15 years; 16-17 years), were randomised 2:1:1 to receive the HSV vaccine, a hepatitis A vaccine (Havrix™; HAV control) or placebo (saline) according to a 0-, 1-, 6-month schedule. Participants and study personnel not involved in the preparation or administration of vaccines were blinded to treatment. Safety and immunogenicity analyses were performed overall and by age (10-15 years; 16-17 years) and HSV serostatus. RESULTS: No statistically significant difference in the percentage of subjects with SAEs was observed between the HSV and saline group, or between the HSV and pooled control (HAV and saline) groups. The HSV vaccine was well tolerated, although a higher incidence of solicited local symptoms was observed in the HSV group than in the control group. Neither age nor HSV serostatus at the time of study entry had an impact on the safety profile of this vaccine. The HSV vaccine was immunogenic regardless of pre-vaccination HSV serostatus. Higher anti-gD geometric mean concentrations were observed in HSV-1 seropositive participants than in HSV-1 seronegative participants. CONCLUSION: The HSV vaccine had an acceptable safety profile, and was well tolerated and immunogenic when administered to girls aged 10-17 years regardless of age or HSV pre-vaccination serostatus.


Subject(s)
Drug-Related Side Effects and Adverse Reactions/epidemiology , Herpes Genitalis/prevention & control , Herpesvirus Vaccines/adverse effects , Herpesvirus Vaccines/immunology , Adolescent , Child , Double-Blind Method , Drug-Related Side Effects and Adverse Reactions/pathology , Female , Herpes Genitalis/immunology , Herpesvirus 2, Human/immunology , Herpesvirus Vaccines/administration & dosage , Humans , Placebos/administration & dosage , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/adverse effects , Vaccines, Subunit/immunology , Viral Envelope Proteins/immunology
3.
J Med Virol ; 84(1): 11-7, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22052690

ABSTRACT

A combined hepatitis A and B vaccine is available since 1996. Two separate open-label primary studies evaluated the immunogenicity and safety of this hepatitis A and B vaccine (720 EI.U of HAV and 20 µg of HBsAg) in 306 healthy subjects aged 17-43 years who received three doses of the vaccine following a 0, 1, and 6 months schedule. These subjects were followed up annually for the next 15 years to evaluate long-term persistence of anti-HAV and anti-HBs antibodies. The subjects whose antibody concentrations fell below the cut-offs between Year 11 and Year 15 (anti-HAV: <15 mIU/ml; anti-HBs: <10 mIU/ml) were offered an additional dose of the appropriate monovalent hepatitis A and/or B vaccine. In subjects who received the additional vaccine dose, a blood sample was collected 1 month after vaccination. At the Year 15 time point, all subjects in Study A and Study B were seropositive for anti-HAV antibodies and 89.3% and 92.9% of subjects in the respective studies had anti-HBs antibody concentrations ≥10 mIU/ml. Four subjects (two in each study) received an additional dose of monovalent hepatitis B vaccine and mounted anamnestic responses to vaccination. No vaccine-related serious adverse events were reported. This study confirms the long-term immunogenicity of the three-dose regimen of the combined hepatitis A and B vaccine, as eliciting long-term persistence of antibodies and immune memory against hepatitis A and B for up to at least 15 years after a primary vaccination.


Subject(s)
Hepatitis A Antibodies/blood , Hepatitis A Vaccines/immunology , Hepatitis B Antibodies/blood , Immunologic Memory , Adolescent , Adult , Female , Follow-Up Studies , Hepatitis A Vaccines/administration & dosage , Humans , Immunization, Secondary/methods , Male , Middle Aged , Time Factors , Vaccination/methods , Young Adult
4.
J Steroid Biochem Mol Biol ; 127(3-5): 374-81, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21762781

ABSTRACT

The chimeric uPA(+/+)-SCID mouse model, transplanted with human hepatocytes, was previously validated as an alternative tool to study in vivo the human steroid metabolism. This humanized mouse model was now applied, in the framework of anti-doping research, to test different nutritional supplements containing steroids. These steroids, intentionally or accidentally added to a nutritional supplement, usually are derivatives of testosterone. Information about the metabolism of these derivatives, which is important to assure their detection, is quite limited. However, due to ethical constraints, human volunteers cannot be used to perform experimental excretion studies. Therefore the chimeric mice were selected to perform three separated excretion studies with superdrol (methasterone), promagnon and also methylclostebol. The urine of the humanized mice was collected 24h after a single dose administration and analyzed by gas chromatography-mass spectrometry (GC-MS). The results indicated the presence of several metabolites including a 3-keto reduced metabolite and numerous hydroxylated metabolites. Also phase 2 metabolism was investigated to update the complete picture of their metabolism.


Subject(s)
Cholesterol/metabolism , Animals , Mice , Mice, SCID
5.
J Viral Hepat ; 18(5): 369-75, 2011 May.
Article in English | MEDLINE | ID: mdl-20384962

ABSTRACT

Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg -/+ and HBeAg -/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0-1-2-12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti-HBs antibodies and serological markers of hepatitis B infection (anti-HBc, HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA). During the 20-year follow-up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti-HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti-HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure.


Subject(s)
Carrier State/prevention & control , Endemic Diseases/prevention & control , Hepatitis B Vaccines/administration & dosage , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/prevention & control , Adolescent , Carrier State/epidemiology , Carrier State/immunology , Child , Child, Preschool , DNA, Viral/blood , Female , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/immunology , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis B virus/pathogenicity , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Humans , Immunization, Secondary , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Longitudinal Studies , Male , Pregnancy , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , Thailand/epidemiology , Young Adult
6.
Eur J Clin Microbiol Infect Dis ; 29(11): 1427-34, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20830499

ABSTRACT

In order to study the hepatitis C virus (HCV) epidemiology in Flanders, Belgium, the HCV genotype of 2,301 patients diagnosed with HCV between 2001 and 2009 was determined. HCV genotyping was conducted using the Versant LiPA 1.0 or Versant LiPA 2.0 assay. To explore the transmission history of a remarkable cluster of the rarely found HCV genotype 5a, face-to-face interviews based on detailed questionnaires and maximum likelihood phylogenetic analysis were performed. HCV genotype 1 was the most prevalent genotype in all provinces, followed by HCV genotype 3 in East Flanders, Antwerp, Flemish Brabant and Limburg. In Brussels, HCV genotype 4 was the second most prevalent genotype. This observation is due to the immigration of patients from the Middle East and Africa. Remarkably, a cluster of HCV genotype 5a was found in West Flanders, where it represents the second most prevalent genotype, accounting for 26.2% of HCV infections. We could not identify one major transmission source explaining the whole HCV genotype 5a epidemic. Instead, several smaller possible transmission chains were identified and confirmed phylogenetically. Overall, the HCV genotype 5a epidemic in West Flanders seems to be mainly associated with blood transfusion and unsafe medical practices.


Subject(s)
Hepacivirus/genetics , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/virology , Belgium/epidemiology , Cluster Analysis , Female , Genotype , Hepacivirus/classification , Hepacivirus/isolation & purification , Humans , Male , Phylogeny , RNA, Viral/analysis , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , Serotyping , Surveys and Questionnaires
7.
J Chromatogr A ; 1178(1-2): 223-30, 2008 Jan 18.
Article in English | MEDLINE | ID: mdl-18078948

ABSTRACT

A quantitative method based on gas chromatography-mass spectrometry (GC-MS) has been developed for the detection of 16 endogenous androgens in the urine of mice. The substances are extracted from 100 microL urine with freshly distilled diethyl ether after alkalinisation. The substances are derivatised with a mixture of N-methyl-N-trimethylsilyltrifluoroacetamide/NH(4)I/ethanethiol (383/1/2, v/w/v) and detected by GC-MS in the selected ion monitoring mode. The results of the method validation indicate good linearity, accuracy and precision, making the method suitable for the quantification of endogenous androgens in mouse urine. The selectivity of the method showed that no interfering peaks were observed at the retention times of the analytes. The method allows for the direct quantification and identification of testosterone and 15 other endogenous androgens at low concentrations (ng/mL) in mouse urine. The applicability of the method is shown by the analysis of a mouse urine. Several endogenous steroids could be detected.


Subject(s)
Androgens/urine , Gas Chromatography-Mass Spectrometry/methods , Androgens/chemistry , Animals , Mice
8.
Travel Med Infect Dis ; 5(3): 171-5, 2007 May.
Article in English | MEDLINE | ID: mdl-17448944

ABSTRACT

BACKGROUND: Hepatitis A and B infections are prevalent worldwide and cause significant morbidity and mortality. A combined vaccine providing dual protection against hepatitis A and B is available (Twinrix, GlaxoSmithKline Biologicals). METHOD: Two cohorts of adults aged 17-43 years were vaccinated with Twinrix according to a 0, 1, 6 months schedule and followed up for 10 years. RESULTS: One month after the primary vaccination course (Month 7), all subjects were seropositive for anti-HAV and all had anti-HBs> or = 10 mIU/ml. At month 120, 100% of subjects (N=34; N=29) in both cohorts were seropositive for anti-HAV; 94.1% and 86.2% of subjects had anti-HBs > or = 10 mIU/ml. The geometric mean concentrations (GMC; mIU/ml) were 373.9 and 674.6 in the two cohorts for anti-HAV, and 103.8 and 320.0, respectively, for anti-HBs. None of the serious adverse events reported throughout the follow-up period were considered by the investigator to be causally related to vaccination. CONCLUSIONS: Combined hepatitis A and B vaccine, Twinrix, is safe, well-tolerated and has demonstrated a highly immunogenic profile. Persistence of anti-HAV and anti-HBs antibodies in adults remains high for at least 10 years after primary vaccination.


Subject(s)
Hepatitis A Vaccines/immunology , Hepatitis A/prevention & control , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Travel , Vaccines, Combined/immunology , Adolescent , Adult , Cohort Studies , Double-Blind Method , Female , Hepatitis A/blood , Hepatitis Antibodies/blood , Hepatitis B/blood , Humans , Male , Middle Aged , Treatment Outcome , Vaccination
9.
Int J STD AIDS ; 18(3): 152-6, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17362544

ABSTRACT

The prevalence of markers for hepatitis B virus (HBV) exposure and active infection in HIV-positive (n=710) and HIV-negative (n=710) pregnant South African women was investigated. The following statistically significant increases in the HIV-positive group were found: anti-hepatitis B core antigen (anti-HBc) (37.3% versus 28.6%; odds ratio [OR]: 1.49); anti-hepatitis B surface antigen (anti-HBs) (29.5% versus 20.1%; OR: 1.66); exposure based on hepatitis B surface antigen (HBsAg) and anti-HBc (39.2% versus 30.1%; OR: 1.49); and exposure based on anti-HBs, anti-HBc and HBsAg (37.1% versus 24.5%; OR: 1.82). However, there was no increase in active HBV infections, with 2.4% of the HIV positives and 2.2% of the HIV negatives being HBV DNA positive. Although the impact that HIV has had on the prevalence of HBV in this population group is not as pronounced as that found in areas of low endemicity (where up to seven-fold increases have been reported), there is a statistically significant increased exposure to HBV.


Subject(s)
HIV Infections/virology , Hepatitis B/virology , Pregnancy Complications, Infectious/virology , Prenatal Diagnosis , Africa South of the Sahara/epidemiology , Case-Control Studies , Female , HIV , HIV Infections/chemically induced , HIV Infections/diagnosis , HIV Infections/epidemiology , Hepatitis B/complications , Hepatitis B/diagnosis , Hepatitis B/epidemiology , Hepatitis B virus , Humans , Pregnancy , Pregnancy Complications, Infectious/blood , Pregnancy Complications, Infectious/epidemiology , Retrospective Studies , South Africa
10.
Acta Gastroenterol Belg ; 68(3): 308-13, 2005.
Article in English | MEDLINE | ID: mdl-16268416

ABSTRACT

This article discusses the use of virologic assays in the diagnosis and management of hepatitis C virus (HCV) and hepatitis B (HBV) infection. The use of virologic tests has become essential in the management of HCV and HBV infection to diagnose viral infection, guide treatment decisions, and assess the virologic response to antiviral therapy. The continuing development of test systems accompanied by new antiviral drugs and novel therapeutic approaches should lead to an optimization of the treatment of HCV infection. Molecular methods for viral testing have become an integral part of the diagnostic and therapeutic management of infections with hepatitis C virus (HCV) and hepatitis B virus (HBV).


Subject(s)
Hepacivirus , Hepatitis Antibodies/analysis , Hepatitis B virus , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Practice Guidelines as Topic , RNA, Viral/analysis , Belgium , Diagnosis, Differential , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis B/virology , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis C/virology , Humans
11.
J Immunol Methods ; 301(1-2): 124-39, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15992817

ABSTRACT

Analyses of cellular immune responses during natural infections and following vaccination with established or candidate vaccines are becoming increasingly important and so are the research tools used to achieve this goal. During a recent evaluation of the analytical performance characteristics of one of these techniques, the interferon-gamma secretion assay, we noticed that following overnight incubation of PBMC with recall antigens (varicella-zoster antigen, Candida albicans antigen or hepatitis B surface antigen) NK cells are frequently the most predominant interferon-gamma-producing cell population. In this study, we monitored the subset distribution of interferon-gamma-producing cells following more extended in vitro culture periods and found that, irrespective of the antigen applied, the contribution of NK cells decreased whereas the importance of T cells and NKT cells rose. Analysis of the subset distribution showed that HBsAg stimulated CD4 cells predominantly whereas Candida antigen and varicella-zoster antigen were better inducers of CD8 responses. No correlation was found between the kinetics of total number of interferon-gamma-producing cells and the changes of concentrations of interferon-gamma in the culture supernatants. Interferon-gamma levels in culture supernatants correlated strongly with the kinetics of T(H) lymphocytes (CD3+, CD4+), CTL (CD3+, CD8+), and NKT cells (CD3+, CD56+). These observations lead us to conclude that methods that enumerate cytokine-secreting cells without determining their phenotype should be interpreted with great care and that an 'elispot' should not be directly considered as the footprint of a T lymphocyte.


Subject(s)
Antigens/immunology , Interferon-gamma/metabolism , Lymphocytes/immunology , Lymphocytes/metabolism , Candida albicans/immunology , Cells, Cultured , Herpesvirus 3, Human/immunology , Humans , Interferon-gamma/biosynthesis , Kinetics , Phenotype , Time Factors
12.
Clin Exp Immunol ; 140(1): 126-37, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15762884

ABSTRACT

The mechanisms causing non-responsiveness to hepatitis B surface antigen (HBsAg) vaccines in man remain elusive. The increased incidence of non-responsiveness in subjects with HLA-DR3(+) or -DR7(+) haplotypes suggests that immune response mechanisms governed by genes of the MHC are involved. Homozygotes for these two haplotypes are found almost exclusively in the non-responder (NR) population. It is conceivable that antigen-presenting cells (APC) of NR are defective in the uptake of HBsAg and that they are unable to present this Ag adequately. Previously, we demonstrated that DR2(+), DR7(+) and DP4(+) NR were able to present HBsAg. In the present paper we demonstrate that six DR0301(+) NR, five of which are homozygous for this marker, were able to take up, process and present HBsAg to HBsAg-specific, DR0301-restricted T cell lines. Non-fractionated peripheral blood mononuclear cells (PBMC) from the DR0301(+) NR did not proliferate to HBsAg in vitro, whereas they proliferated vigorously upon stimulation with tetanus toxoid, thus ruling out the presence of a generalized immunodeficiency. We therefore conclude that HLA-DR0301(+) NR vaccinees are not deficient in their HBsAg-presentation. Because it was demonstrated that recently activated T cells can apparently bypass the requirement for B7, we may have overlooked the role of the B7-co-stimulation in our set-up that used HBsAg-specific T cell lines. Therefore we examined the expression of B7 co-stimulatory molecules on NR-APC. CD86 was normally present on these cells and was not down-regulated after culturing the PBMC in the presence of HBsAg. We conclude that CD86 expression on CD14(+) monocytes of DR0301- and DR07-homozygous poor responders is not deficient and cannot be the mechanism underlying the non-responsiveness of these subjects.


Subject(s)
Antigen Presentation/immunology , Antigens, CD/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Antigen-Presenting Cells/immunology , B7-1 Antigen/immunology , B7-2 Antigen , Cell Line , Coculture Techniques/methods , HLA-DP Antigens/immunology , HLA-DP beta-Chains , HLA-DR Antigens/immunology , HLA-DR3 Antigen , Humans , Immunity, Cellular/immunology , Leukocyte Count , Leukocytes, Mononuclear/immunology , Lipopolysaccharide Receptors/immunology , Membrane Glycoproteins/immunology , T-Lymphocytes/immunology
13.
Liver Int ; 25(2): 201-13, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15780040

ABSTRACT

A growing body of evidence indicates that human immunodeficiency virus (HIV)-positive individuals are more likely to be infected with hepatitis B virus (HBV) than HIV-negative individuals, possibly as a result of shared risk factors. There is also evidence that HIV-positive individuals who are subsequently infected with HBV are more likely to become HBV chronic carriers, have a high HBV replication rate, and remain hepatitis Be antigen positive for a much longer period. In addition, it is evident that immunosuppression brought about by HIV infection may cause reactivation or reinfection in those previously exposed to HBV. Furthermore, HIV infection exacerbates liver disease in HBV co-infected individuals, and there is an even greater risk of liver disease when HIV and HBV co-infected patients are treated with highly active anti-retroviral therapy (HAART). Complicating matters further, there have been several reports linking HIV infection to 'sero-silent' HBV infections, which presents serious problems for diagnosis, prevention, and control. In sub-Saharan Africa, where both HIV and HBV are endemic, little is known about the burden of co-infection and the interaction between these two viruses. This paper reviews studies that have investigated HIV and HBV co-infection in sub-Saharan Africa, against a backdrop of what is currently known about the interactions between these two viruses.


Subject(s)
AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/prevention & control , Communicable Disease Control/organization & administration , Hepatitis B/epidemiology , Hepatitis B/prevention & control , AIDS-Related Opportunistic Infections/drug therapy , Africa South of the Sahara/epidemiology , Antiretroviral Therapy, Highly Active/methods , Antiviral Agents/therapeutic use , Comorbidity , Developing Countries , Female , Hepatitis B/drug therapy , Hepatitis B Vaccines/administration & dosage , Hepatitis B virus/isolation & purification , Humans , Male , Prevalence , Program Development , Program Evaluation , Risk Assessment , Severity of Illness Index , Sex Distribution , Vaccination/methods
14.
Arch Virol ; 150(2): 247-59, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15480855

ABSTRACT

Hepatitis B surface antigen, when produced in yeast (rHBsAg), is capable of binding to cells that express the lipopolysaccharide coreceptor CD14. This interaction is enhanced by a serum protein, the lipopolysaccharide binding protein (LBP). Here we report that most of the rHBsAg particles that attached to monocytes at 0 degrees C, were not endocytosed but were released back into the serum-containing binding buffer at 37 degrees C. Additionally, serum-dependent binding at 37 degrees C was weak when compared to the serum-dependent attachment at 0 degrees C. Pre-incubation at 37 degrees C of cells together with serum did not abolish binding of freshly added rHBsAg at 0 degrees C. However, pre-incubation of rHBsAg with serum at 37 degrees C reduced attachment to cells following incubation at 0 degrees C. Soluble CD14 and LBP, two serum proteins which can act as phospholipid transfer molecules, were shown not to be responsible for the inhibitory effect. Pre-incubation at 37 degrees C of rHBsAg in serum-free hepatoma cell line-conditioned media resulted in a pronounced reduction in subsequent binding to cells at 0 degrees C. These observations suggest that the temperature-dependent inhibitory effect is caused by serum factors that are probably secreted by hepatocytes.


Subject(s)
Hepatitis B Surface Antigens/immunology , Monocytes/immunology , Serum/immunology , Temperature , Acute-Phase Proteins , Animals , CHO Cells , Carrier Proteins , Cell Line, Tumor , Cricetinae , Culture Media, Conditioned , Hepatitis B Surface Antigens/biosynthesis , Hepatitis B Surface Antigens/genetics , Humans , Lipopolysaccharide Receptors , Membrane Glycoproteins , Mice , Protein Binding , Recombinant Proteins/biosynthesis , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Time Factors
15.
J Viral Hepat ; 11(3): 198-205, 2004 May.
Article in English | MEDLINE | ID: mdl-15117321

ABSTRACT

In spite of advances made in our understanding of the biology of the hepatitis C virus (HCV), the epidemiology and natural history of HCV infection, and the treatment of chronic hepatitis C, the development and worldwide implementation of a comprehensive prevention and control strategy remains necessary. A World Health Organization informal consultation with the Viral Hepatitis Prevention Board was convened and met in Geneva, Switzerland, 13-14 May 2002, to review epidemiological and public health aspects of HCV infection, and the various prevention and control strategies that are currently in place. Based on the presentations and discussions, a number of specific recommendations were made, which should be considered in conjunction with previously published recommendations.


Subject(s)
Hepatitis C/prevention & control , Antiviral Agents/therapeutic use , Female , Health Education , Hepatitis C/drug therapy , Hepatitis C/etiology , Hepatitis C/transmission , Humans , Male , Risk-Taking
16.
J Immunol Methods ; 286(1-2): 167-85, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15087231

ABSTRACT

Different single-cell analyses for the detection of antigen-specific T cells based on antigen-triggered induction of cytokine production (elispot, intracellular cytokine staining, cytokine secretion assay, etc.) have been analyzed. In this paper we present the data of a thorough validation of the IFNgamma Secretion Assay (ISA, Miltenyi Biotec, Bergisch Gladbach, Germany). In this assay the secreted IFNgamma is bound to the cell surface and is then stained as an artificial surface molecule and analyzed by flow-cytometry. The introduction of five quality criteria markedly improved the reproducibility of this assay and made it very reliable (intra-assay variability<5%; inter-assay variability<20%). Recovery experiments further demonstrated that almost 100% of IFNgamma(+) labeled cells could be detected by this technology. In order to analyze which cell subsets contribute to IFNgamma-production, we compared the results obtained in different individuals after VZAg-stimulation. Three different IFNgamma-secretion patterns could be discerned. In Pattern 1 there is a predominant and almost equal contribution of T cells and NK cells with a minor contribution of CD3(+)CD56(+) and B cells. Pattern 2, which is most abundant, is characterized by a predominance of NK cells (60-70%). Pattern 3 differs from the previous one in its minor contribution of NK cells. Here T cells predominate the IFNgamma secretion. These results clearly demonstrate that the IFNgamma(+) subset distribution after VZAg-stimulation is not uniform and differs individually. Furthermore, the ISA-technology proves to be very useful in vaccine research. This was demonstrated by testing the IFNgamma(+) secretion pattern after HBsAg-stimulation in PBMC from HBsAg-vaccinated individuals.


Subject(s)
Flow Cytometry/methods , Interferon-gamma/biosynthesis , Interferon-gamma/metabolism , Leukocytes, Mononuclear/immunology , Lymphocyte Subsets/immunology , Antibodies, Viral/immunology , Antigens, Viral/immunology , Cell Division/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Herpesvirus 3, Human/immunology , Humans , Interferon-gamma/immunology , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/cytology , Lymphocyte Activation/immunology , Reproducibility of Results , T-Lymphocytes/immunology
17.
J Viral Hepat ; 10(6): 460-6, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14633181

ABSTRACT

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the hepatitis C virus (HCV) load and a better response rate. Naive chronically infected HCV patients (n = 454) were randomized into two arms to receive either induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily during a period of 8 weeks (arm A); or treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for a period of 8 weeks (arm B). After week 8, interferon treatment in both arms was 3 MU s.c. TIW for a total period of 12 months. In both arms, ribavirin (1000-1200 mg orally per day) was added at week 4. Induction treatment resulted in a higher virological response at week 8 of treatment (66%vs 47%; P < 0.01). However, response at the end of treatment and at 6 months follow-up was not different (53%vs 50%, 41%vs 33%). The occurrence of adverse events and the drop-out rate were similar in both arms. Although an early virological response is observed more frequently in the induction treatment, end of treatment response and sustained responses did not differ.


Subject(s)
Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Interferon-alpha/therapeutic use , Ribavirin/administration & dosage , Ribavirin/therapeutic use , Adolescent , Adult , Aged , Alanine Transaminase/blood , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Belgium , Drug Therapy, Combination , Genotype , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/pharmacology , Liver Cirrhosis , Middle Aged , Netherlands , RNA, Viral/blood , Recombinant Proteins , Ribavirin/pharmacology , Viral Load
18.
Lancet ; 362(9389): 1065-71, 2003 Sep 27.
Article in English | MEDLINE | ID: mdl-14522539

ABSTRACT

Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world. Effective vaccines against hepatitis A have been available since 1992, and they provide long-term immunity against the infection. However, there is no worldwide consensus on how long protection will last or whether there will be a need for hepatitis A virus (HAV) booster vaccinations in the future. In most countries, booster-vaccination policy is guided by manufacturers' recommendations, national authorities, or both. In June, 2002, a panel of international experts met to review the long-term immunogenicity and protection conferred by HAV vaccine in different population groups. Data have shown that after a full primary vaccination course, protective antibody amounts persist beyond 10 years in healthy individuals, and underlying immune memory provides protection far beyond the duration of anti-HAV antibodies. The group concluded that there is no evidence to lend support to HAV booster vaccination after a full primary vaccination course in a healthy individual. However, further investigations are needed before deciding if boosters can be omitted in special patient-groups.


Subject(s)
Hepatitis A Vaccines/administration & dosage , Hepatitis A/prevention & control , Immunization, Secondary/statistics & numerical data , Adolescent , Adult , Age Factors , Child , Child, Preschool , Endemic Diseases/prevention & control , Hepatitis A/immunology , Hepatitis A Vaccines/immunology , Humans , Immunization Schedule , Immunologic Memory/immunology , Infant
19.
Biochem Biophys Res Commun ; 308(2): 375-8, 2003 Aug 22.
Article in English | MEDLINE | ID: mdl-12901879

ABSTRACT

Successful transplantation of xenogeneic hepatocytes into uPA-transgenic SCID mice depends on the zygosity of the recipient mice. Normally, the difference between homozygous and heterozygous animals is determined via a quantitative Southern blot. We sequenced a part of the mouse genome that is eliminated upon integration of the transgene in the genome. Based on that sequence we developed a multiplex PCR that allows the unambiguous discrimination of negative, heterozygous, and homozygous uPA-transgenic SCID mice in a single day procedure. The speed of the procedure is an essential quality because transplantation of xenogeneic hepatocytes into uPA-SCID mice should be done as soon as possible after birth.


Subject(s)
Urokinase-Type Plasminogen Activator/genetics , Animals , Animals, Newborn , Base Sequence , Disease Models, Animal , Hepatitis B/etiology , Hepatitis C/etiology , Hepatocytes/transplantation , Heterozygote , Homozygote , Humans , Mice , Mice, SCID , Mice, Transgenic , Molecular Sequence Data , Plasmids/genetics , Transplantation, Heterologous
20.
Sex Transm Infect ; 79(2): 157-9, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12690142

ABSTRACT

OBJECTIVES: To assess to what extent hepatitis B vaccination of sex workers in Ghent, Belgium, is successful within the context of the existing health services and to compare this with alternative approaches such as outreach programmes; to compare two hepatitis B vaccination schemes in the outreach programme for sex workers. METHODS: Testing all first contacts (n = 1096) in the outreach programme for hepatitis B virus (HBV) markers assessed success of hepatitis B vaccination in routine services. The performance of the outreach service was measured by counting the number of sex workers who started hepatitis B vaccination in the programme. The hepatitis B vaccination schemes were assessed by analysing the number of people completing the vaccination. RESULTS: Naturally acquired HBV was found in 11.9% of 1096 sex workers (0.6% HBsAg), and 7% were vaccinated in existing services. In contrast, hepatitis B vaccination using outreach methodology was able to achieve higher vaccination rates: among non-immune sex workers 82.8% received the first dose of vaccine, and 71.5% the second. If given 1 month later, 67.9% received the third dose, in contrast with 47.9%, when given 6 months later. CONCLUSIONS: Existing services are not successful in vaccinating sex workers for HBV, in contrast with specifically targeted outreach services. Shorter intervals between vaccine doses gave better compliance.


Subject(s)
Hepatitis B Vaccines , Hepatitis B/prevention & control , Sex Work , Adolescent , Adult , Aged , Belgium , Female , Humans , Immunization Programs , Male , Middle Aged , Patient Compliance , Risk-Taking , Vaccination/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...